Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer
Closed
Phase 2
This trial is looking at pembrolizumab to treat triple negative breast cancer. If breast cancer doesn’t have receptors for the hormones oestrogen or progesterone, or for the protein HER2, it is called triple negative breast cancer.
The trial is for people whose cancer has spread to another part of their body.
Recruitment start: 1 October 2015
Recruitment end: 30 November 2016
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
Experimental Cancer Medicine Centre (ECMC)
Merck Sharp & Dohme Ltd
Last reviewed: 11 Sept 2016
CRUK internal database number: 13431
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
